T1	Intoxication_considerations 0 179	Subjects with a known or suspected alcohol or drug abuse which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.
T2	Qualifier 192 208	life threatening
T3	Condition 209 215	asthma
R1	Has_qualifier Arg1:T3 Arg2:T2	
T4	Condition 231 245	asthma episode
T5	Qualifier 251 270	required intubation
T6	Procedure 260 270	intubation
R2	multi Arg1:T5 Arg2:T6	
R3	Has_qualifier Arg1:T4 Arg2:T5	
T7	Condition 298 309	hypercapnea
T8	Condition 311 329	respiratory arrest
T9	Condition 333 349	hypoxic seizures
T10	Temporal 350 374	within the last 6 months
*	OR T7 T8 T9
T11	Scope 298 349	hypercapnea, respiratory arrest or hypoxic seizures
R4	Has_temporal Arg1:T11 Arg2:T10	
R5	Has_scope Arg1:T4 Arg2:T11	
T12	Scope 231 374	asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months
R6	Subsumes Arg1:T3 Arg2:T12	
T13	Condition 379 412	lower respiratory tract infection
T14	Temporal 413 449	within 7 days of the screening visit
R7	Has_temporal Arg1:T13 Arg2:T14	
T15	Reference_point 434 449	screening visit
R8	multi Arg1:T14 Arg2:T15	
T16	Condition 476 520	chronic obstructive pulmonary disease (COPD)
T17	Qualifier 524 529	other
T18	Condition 530 551	respiratory disorders
T19	Qualifier 562 568	active
T20	Condition 569 581	tuberculosis
T21	Condition 583 594	lung cancer
T22	Condition 596 610	bronchiectasis
T23	Condition 612 623	sarcoidosis
T24	Condition 625 638	lung fibrosis
T25	Condition 640 662	pulmonary hypertension
T26	Condition 664 690	interstitial lung diseases
T27	Qualifier 694 699	other
T28	Qualifier 700 706	active
T29	Condition 707 725	pulmonary diseases
R9	Has_qualifier Arg1:T29 Arg2:T28	
R10	Has_qualifier Arg1:T29 Arg2:T27	
*	OR T26 T29 T25 T24 T23 T22
R11	Has_qualifier Arg1:T20 Arg2:T19	
R12	Has_qualifier Arg1:T18 Arg2:T17	
*	OR T16 T18
T30	Scope 476 551	chronic obstructive pulmonary disease (COPD) or other respiratory disorders
T31	Scope 562 725	active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
R13	Subsumes Arg1:T30 Arg2:T31	
T32	Condition 739 755	hypersensitivity
T33	Condition 756 767	intolerance
T34	Drug 818 825	lactose
T35	Drug 827 845	magnesium stearate
*	OR T34 T35
T36	Drug 775 807	components of the study inhalers
T37	Scope 818 845	lactose, magnesium stearate
R14	Subsumes Arg1:T36 Arg2:T37	
*	OR T33 T32
T38	Scope 739 767	hypersensitivity/intolerance
R15	AND Arg1:T38 Arg2:T36	
T39	Observation 877 884	history
T40	Qualifier 888 894	severe
T41	Drug 895 907	milk protein
T42	Condition 908 915	allergy
R16	AND Arg1:T42 Arg2:T41	
R17	Has_qualifier Arg1:T42 Arg2:T40	
R18	Has_temporal Arg1:T42 Arg2:T39	
T43	Non-query-able 922 959	in the opinion of the study physician
T44	Condition 961 990	contraindicates participation
R19	AND Arg1:T42 Arg2:T44	
*	OR T38 T42
T45	Condition 1264 1291	hematological abnormalities
T46	Qualifier 1049 1071	clinically significant
T47	Qualifier 1075 1094	rapidly progressing
T48	Condition 1107 1121;1278 1291	cardiovascular abnormalities
T49	Qualifier 1098 1106	unstable
*	OR T46 T47 T49
T50	Scope 1049 1106	clinically significant or rapidly progressing or unstable
T51	Condition 1123 1135;1278 1291	neurological abnormalities
T52	Condition 1137 1151;1278 1291	cardiovascular abnormalities
T53	Condition 1153 1165;1278 1291	neurological abnormalities
T54	Condition 1167 1172;1278 1291	renal abnormalities
T55	Condition 1174 1181;1278 1291	hepatic abnormalities
T56	Condition 1183 1196;1278 1291	immunological abnormalities
T57	Condition 1198 1207;1278 1291	endocrine abnormalities
T58	Qualifier 1219 1231	uncontrolled
T59	Condition 1232 1240	diabetes
T60	Condition 1244 1259	thyroid disease
*	OR T59 T60
T61	Scope 1232 1259	diabetes or thyroid disease
R20	Has_qualifier Arg1:T61 Arg2:T58	
R21	Subsumes Arg1:T57 Arg2:T61	
*	OR T48 T51 T52 T53 T54 T55 T56 T57 T45
T62	Qualifier 1301 1313	uncontrolled
T63	Scope 1107 1291	cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities
R22	Has_scope Arg1:T63 Arg2:T50	
R23	Has_qualifier Arg1:T63 Arg2:T62	
T64	Observation 1015 1025	Historical
T65	Temporal 1029 1036	current
*	OR T64 T65
T66	Scope 1015 1036	Historical or current
R24	Has_scope Arg1:T63 Arg2:T66	
T67	Non-representable 1315 1551	Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study.
T68	Procedure 1585 1594	treatment
T69	Drug 1634 1644	omalizumab
T70	Drug 1646 1657	mepolizumab
T71	Drug 1663 1669	asthma
*	OR T69 T70 T71
T72	Scope 1634 1669	omalizumab, mepolizumab, for asthma
R25	Has_scope Arg1:T68 Arg2:T72	
T73	Competing_trial 1672 1878	Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer.
T74	Non-query-able 1880 2134	A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Propeller Health employee.
